☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE may reject Inhaled Insulin

The National Institute of Health and Clinical Excellence (NICE) has issued an Appraisal Consultation Document for Inhaled Insulin (Exubera)® for Type I and Type II Diabetes.

This Appraisal is a preliminary recommendation and subject to change before publication however this document states that NICE do not recommend Inhaled Insulin for use on the NHS unless it is part of a clinical trial.

The BBC and Guardian have already reported this information.

Inhaled Insulin has many limitations in general use as discussed already. In addition to these clinical concerns this new product is likely to cost more at £1,100 per patient per year compared to £300 for injected insulin.

Action: Clinicians involved in the treatment of diabetes may be asked about this product by patients and should be aware of current information.

Share 'NICE may reject Inhaled Insulin' by emailShare 'NICE may reject Inhaled Insulin' on FacebookShare 'NICE may reject Inhaled Insulin' on TwitterShare 'NICE may reject Inhaled Insulin' on LinkedInShare 'NICE may reject Inhaled Insulin' on reddit


One Comment to “NICE may reject Inhaled Insulin”

  1. […] previously reported, NICE were not expected to widely endorse this product. Additionally, the Scottish Medicines […]

    Pingback by NICE guidance on Inhaled Insulin | Prescribing Advice for GPs — December 13, 2006 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.